# ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC

> **NCT05198154** · — · RECRUITING · sponsor: **Fang Wu** · enrollment: 100 (estimated)

## Conditions studied

- Advanced Lung Non-Small Cell Carcinoma

## Interventions

- **DIAGNOSTIC_TEST:** ctDNA detection

## Key facts

- **NCT ID:** NCT05198154
- **Lead sponsor:** Fang Wu
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-24
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-04-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05198154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05198154, "ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05198154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*